|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19756212A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
JP2002522499A
(ja)
*
|
1998-08-12 |
2002-07-23 |
スミスクライン・ビーチャム・コーポレイション |
カルシウム分解化合物
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
ATE278421T1
(de)
*
|
2000-08-11 |
2004-10-15 |
Wyeth Corp |
Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
|
|
AR035205A1
(es)
|
2000-09-29 |
2004-05-05 |
Glaxo Group Ltd |
Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
US8067415B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
US8067457B2
(en)
|
2005-11-01 |
2011-11-29 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of CCR2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
MX2010014310A
(es)
|
2008-06-24 |
2011-02-15 |
Topotarget As |
Derivados de acido escuarico como inhibidores de la nicotinamida.
|
|
CN102186822A
(zh)
|
2008-08-29 |
2011-09-14 |
顶标公司 |
新脲和硫脲衍生物
|
|
EP2453883A1
(en)
|
2009-07-17 |
2012-05-23 |
Topo Target A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
AR082886A1
(es)
|
2010-09-03 |
2013-01-16 |
Forma Therapeutics Inc |
Compuestos y composiciones farmaceuticas que los contienen
|
|
CN106986856A
(zh)
|
2010-09-03 |
2017-07-28 |
福马Tm有限责任公司 |
作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
|
|
AR082885A1
(es)
|
2010-09-03 |
2013-01-16 |
Genentech Inc |
Compuestos y composiciones para la inhibicion de nampt
|
|
RU2596185C2
(ru)
*
|
2010-09-29 |
2016-08-27 |
Интервет Интернэшнл Б.В. |
N-гетероарильные соединения
|
|
US20120122924A1
(en)
|
2010-11-15 |
2012-05-17 |
Abbott Laboratories |
Nampt inhibitors
|
|
SG10202010119TA
(en)
|
2010-11-15 |
2020-11-27 |
Abbvie Inc |
NAMPT And Rock Inhibitors
|
|
JP5978293B2
(ja)
|
2011-05-04 |
2016-08-24 |
フォーマ ティーエム， エルエルシー． |
Ｎａｍｐｔを阻害するための新規な化合物および組成物
|
|
JP5872027B2
(ja)
|
2011-05-09 |
2016-03-01 |
フォーマ ティーエム， エルエルシー． |
ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
US20130303509A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
|
AR091022A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
|
EP2925750A1
(en)
|
2012-11-29 |
2015-10-07 |
Karyopharm Therapeutics, Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
JP6397010B2
(ja)
|
2013-07-03 |
2018-09-26 |
カリオファーム セラピューティクス，インコーポレイテッド |
置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
WO2017031323A1
(en)
|
2015-08-18 |
2017-02-23 |
Karyopharm Therapeutics Inc. |
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
|
|
US10858347B2
(en)
|
2015-12-31 |
2020-12-08 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
EA201990890A1
(ru)
|
2016-10-18 |
2019-10-31 |
|
Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
EP3787612A4
(en)
|
2018-05-04 |
2021-11-17 |
Remedy Plan, Inc. |
CANCER TREATMENTS AGAINST CANCER STEM CELLS
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
PH12022551081A1
(en)
|
2019-11-06 |
2024-06-19 |
Remedy Plan Inc |
Cancer treatments targeting cancer stem cells
|
|
CA3217380A1
(en)
|
2021-05-13 |
2022-11-17 |
Yushma Bhurruth-Alcor |
Nampt inhibitors and uses thereof
|